Zacks Research Comments on Exelixis, Inc.'s Q4 2024 Earnings (NASDAQ:EXEL)

Exelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Zacks Research dropped their Q4 2024 earnings per share estimates for shares of Exelixis in a research note issued to investors on Monday, April 8th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnings of $0.31 per share for the quarter, down from their previous forecast of $0.33. The consensus estimate for Exelixis' current full-year earnings is $1.22 per share. Zacks Research also issued estimates for Exelixis' Q1 2026 earnings at $0.33 EPS.

Several other research firms also recently issued reports on EXEL. Barclays lifted their price target on Exelixis from $24.00 to $25.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 30th. Royal Bank of Canada boosted their target price on shares of Exelixis from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday, February 7th. Citigroup began coverage on shares of Exelixis in a research note on Friday, December 15th. They issued a "buy" rating and a $31.00 target price for the company. William Blair reissued an "outperform" rating on shares of Exelixis in a research note on Friday, January 26th. Finally, TheStreet raised shares of Exelixis from a "c+" rating to a "b-" rating in a research note on Monday, March 18th. Five equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $26.29.

Exelixis Trading Up 1.6 %

Shares of NASDAQ:EXEL traded up $0.37 during midday trading on Tuesday, hitting $23.72. 1,294,084 shares of the stock were exchanged, compared to its average volume of 2,318,453. The stock has a market cap of $7.19 billion, a P/E ratio of 37.06, a PEG ratio of 0.61 and a beta of 0.54. Exelixis has a twelve month low of $18.08 and a twelve month high of $24.34. The company has a 50 day moving average price of $22.22 and a 200-day moving average price of $22.09.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.02. The business had revenue of $479.65 million during the quarter, compared to the consensus estimate of $481.23 million. Exelixis had a return on equity of 8.57% and a net margin of 11.35%.

Insider Transactions at Exelixis

In other news, Director David Edward Johnson bought 190,000 shares of the firm's stock in a transaction dated Wednesday, February 21st. The stock was acquired at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now owns 1,100,730 shares of the company's stock, valued at $22,785,111. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director David Edward Johnson bought 190,000 shares of the firm's stock in a transaction dated Wednesday, February 21st. The stock was acquired at an average price of $20.70 per share, for a total transaction of $3,933,000.00. Following the acquisition, the director now owns 1,100,730 shares of the company's stock, valued at $22,785,111. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Patrick J. Haley sold 47,020 shares of the business's stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $21.45, for a total value of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares of the company's stock, valued at approximately $8,255,375.70. The disclosure for this sale can be found here. Company insiders own 2.90% of the company's stock.

Hedge Funds Weigh In On Exelixis

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in Exelixis by 4.9% in the 1st quarter. BlackRock Inc. now owns 36,214,174 shares of the biotechnology company's stock worth $702,917,000 after acquiring an additional 1,683,880 shares during the period. Vanguard Group Inc. boosted its stake in shares of Exelixis by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 31,284,832 shares of the biotechnology company's stock valued at $490,546,000 after buying an additional 220,099 shares during the last quarter. State Street Corp boosted its stake in shares of Exelixis by 3.4% during the 3rd quarter. State Street Corp now owns 13,019,900 shares of the biotechnology company's stock valued at $204,152,000 after buying an additional 423,520 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Exelixis by 4.4% during the 1st quarter. Geode Capital Management LLC now owns 4,768,099 shares of the biotechnology company's stock valued at $92,549,000 after buying an additional 201,810 shares during the last quarter. Finally, First Trust Advisors LP boosted its stake in shares of Exelixis by 24.1% during the 1st quarter. First Trust Advisors LP now owns 4,752,734 shares of the biotechnology company's stock valued at $92,251,000 after buying an additional 924,189 shares during the last quarter. Hedge funds and other institutional investors own 85.27% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.